HEPA - Hepion climbs 39% on pre-clinical data for lead asset

• Nano-cap biotech Hepion Pharmaceuticals ( NASDAQ: HEPA ) jumped ~39% pre-market Wednesday on rising volumes after the company announced new pre-clinical findings to support its lead drug candidate, rencofilstat.
• The study investigated the combined effect of rencofilstat and anti-cancer proteasome inhibitor ixazomib on the killing of cultured prostate cancer cells.
• According to Hepion ( HEPA ), the results indicated that rencofilstat could synergistically increase the effect of proteasome inhibitors and enhance in vitro cancer-killing properties of ixazomib.
• The data also suggested that rencofilstat could broaden “the use of proteosome inhibitors for existing applications, or possibly for other cancers, such as prostate cancer,” the company added.
• About 1.4M Hepion ( HEPA ) shares have changed hands in the pre-market so far compared to the 65-day average of ~322.8K.
• Read about another nonclinical study supporting the potential of rencofilstat in liver cancer.

For further details see: